Hallmarks of Cancer Cell
暂无分享,去创建一个
[1] N. Ferrara. Vascular Endothelial Growth Factor , 2009, Arteriosclerosis, thrombosis, and vascular biology.
[2] M. Karin,et al. Immunity, Inflammation, and Cancer , 2010, Cell.
[3] G. Evan,et al. p53 — a Jack of all trades but master of none , 2009, Nature Reviews Cancer.
[4] C. Sonnenschein,et al. The aging of the 2000 and 2011 Hallmarks of Cancer reviews: A critique , 2013, Journal of Biosciences.
[5] Sven Diederichs,et al. The hallmarks of cancer , 2012, RNA biology.
[6] Alberto Mantovani,et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. , 2009, Carcinogenesis.
[7] A. Celeghin,et al. Epstein-Barr virus and telomerase: from cell immortalization to therapy , 2014, Infectious Agents and Cancer.
[8] D. Sabatini,et al. Cancer Cell Metabolism: Warburg and Beyond , 2008, Cell.
[9] M. Blasco. Telomeres and human disease: ageing, cancer and beyond , 2005, Nature Reviews Genetics.
[10] J. Bartek,et al. The DNA-damage response in human biology and disease , 2009, Nature.
[11] I. Fidler,et al. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited , 2003, Nature Reviews Cancer.
[12] T. Chan,et al. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. , 2013, The Journal of clinical endocrinology and metabolism.
[13] Amit Verma,et al. Cancer biomarkers - current perspectives. , 2010, The Indian journal of medical research.
[14] J. Schlessinger,et al. Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.
[15] L. Cantley,et al. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.
[16] Frederick A. Dick,et al. Molecular mechanisms underlying RB protein function , 2013, Nature Reviews Molecular Cell Biology.
[17] D. Sabatini,et al. Cancer cell metabolism: one hallmark, many faces. , 2012, Cancer discovery.
[18] Tomas Lindahl,et al. Repair and genetic consequences of endogenous DNA base damage in mammalian cells. , 2004, Annual review of genetics.
[19] Russell G. Jones,et al. Tumor suppressors and cell metabolism: a recipe for cancer growth. , 2009, Genes & development.
[20] D. Lane,et al. p53, guardian of the genome , 1992, Nature.
[21] J. Geschwind,et al. Tumor glycolysis as a target for cancer therapy: progress and prospects , 2013, Molecular Cancer.
[22] G. Berx,et al. Involvement of members of the cadherin superfamily in cancer. , 2009, Cold Spring Harbor perspectives in biology.
[23] G. Semenza. HIF-1: upstream and downstream of cancer metabolism. , 2010, Current opinion in genetics & development.
[24] L. Coussens,et al. Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity , 2010, Cancer and Metastasis Reviews.
[25] H. Dvorak,et al. Heterogeneity of the Tumor Vasculature , 2010, Seminars in thrombosis and hemostasis.
[26] Y. Shyr,et al. Transforming Growth Factor-β Signaling–Deficient Fibroblasts Enhance Hepatocyte Growth Factor Signaling in Mammary Carcinoma Cells to Promote Scattering and Invasion , 2008, Molecular Cancer Research.
[27] I. Fidler,et al. AACR centennial series: the biology of cancer metastasis: historical perspective. , 2010, Cancer research.
[28] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[29] Marius Raica,et al. Angiogenesis in pre-malignant conditions. , 2009, European journal of cancer.
[30] S. Elledge,et al. The DNA damage response: making it safe to play with knives. , 2010, Molecular cell.
[31] D. Peeper,et al. The essence of senescence. , 2010, Genes & development.
[32] R. DePinho,et al. Telomeres and telomerase in cancer. , 2010, Carcinogenesis.
[33] T. Halazonetis,et al. Genomic instability — an evolving hallmark of cancer , 2010, Nature Reviews Molecular Cell Biology.
[34] A. Velez,et al. Tumor-suppressor Genes, Cell Cycle Regulatory Checkpoints, and the Skin , 2015, North American journal of medical sciences.
[35] C. Vajdic,et al. Cancer incidence and risk factors after solid organ transplantation , 2009, International journal of cancer.
[36] D. Feldser,et al. Short telomeres limit tumor progression in vivo by inducing senescence. , 2007, Cancer cell.
[37] R. Schreiber,et al. Immune‐mediated dormancy: an equilibrium with cancer , 2008, Journal of leukocyte biology.
[38] Yosef Yarden,et al. Roles for growth factors in cancer progression. , 2010, Physiology.
[39] M. Esteller,et al. Aberrant epigenetic landscape in cancer: how cellular identity goes awry. , 2010, Developmental cell.
[40] Varda Rotter,et al. Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. , 2011, Genes & cancer.
[41] S. Cory,et al. The Bcl-2 apoptotic switch in cancer development and therapy , 2007, Oncogene.
[42] S. Lowe,et al. Intrinsic tumour suppression , 2004, Nature.
[43] J. Wischhusen,et al. Cancer Stem Cell Immunology: Key to Understanding Tumorigenesis and Tumor Immune Escape? , 2014, Front. Immunol..
[44] G. Saretzki,et al. DNA damage in telomeres and mitochondria during cellular senescence: is there a connection? , 2007, Nucleic acids research.
[45] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[46] D. Quail,et al. Microenvironmental regulation of tumor progression and metastasis , 2014 .